(Boursier.com) — During the first half of 2022, the Group Predilife achieved a turnover of 151.47 kE (39.21 kE in 2021), an increase of 286%. A third comes from the sale of MammoRisk tests to doctors and hospitals and two thirds to companies, first and foremost Allianz and Nuoma Mutuelle.
“The first half of 2022 was marked by the growth in sales of MammoRisk tests to hospitals but above all by the acceleration in sales of the predictive assessments to companies launched in the fall of 2021. Since the start of the year, we have multiplied signatures with companies adopting this solution for their employees, in sectors as varied as finance, agri-food, IT or distribution.This diversity of client companies demonstrates the breadth of the market and reinforces the Predilife’s confidence in the continued upward trend in its activity in the second half of 2022”, indicates Stéphane Ragusa, Chairman and Chief Executive Officer of the company.
The increase in expenses was concomitant with a drop in expenses, the two combined effects allowing a reduction in the half-year loss to -1.65 million euros (-1.84 ME at June 30, 2021).
Cash at June 30, 2022 was increased on July 11 by 1.75 ME after the Océane issue launched in June, i.e. a total of 3.2 ME.
Predilife will continue in the second half of 2022 its commercialization strategy with companies by opening up to new sectors of activity including luxury, media, construction and catering. Growth in the second half should be confirmed thanks to a diversified client portfolio.